



Montgomery
218 Commerce Street
P.O. Box 4160
Montgomery, AL 36103-4160

Atlanta
4200 Northside Parkway
Building One, Suite 100
Atlanta, GA 30327

(800) 898-2034

BeasleyAllen.com

P. Leigh O'Dell
leigh.odell@beasleyallen.com

October 18, 2019

Honorable Freda L. Wolfson, U.S.D.J.
United States District Court
Clarkson S. Fisher Building & US Courthouse
402 East State Street
Trenton, NJ 08608

**Re: *In Re: Johnson & Johnson Talcum Powder Products Marketing,
Sales Practices and Products Liability Litigation (MDL No. 2738)***

Dear Judge Wolfson:

In a press release issued today, Johnson & Johnson acknowledged that Johnson's Baby Powder tested positive for asbestos and a voluntary recall was initiated. (*See Exhibit A*). Other statements by Johnson & Johnson published in the media report that the recall involves 33,000 bottles of the product. The FDA commissioned independent testing of Johnson's Baby Powder and confirmed the presence of chrysotile asbestos in Lot #22318RB. The source of the talc in the recalled lot is the same that Johnson & Johnson has used for all its talcum powder products since 2003.

The PSC writes to bring this development to the Court's attention and to inform the Court of its efforts to obtain additional information. The PSC has filed a Freedom of Information Act (FOIA) request with the U.S. Food and Drug Administration to obtain documents regarding the third-party lab that performed the testing, the test results, the testing procedures, and any communications regarding the lot that tested positive. The PSC has also requested that Johnson & Johnson Defendants, as a part of their ongoing duty to supplement pending discovery requests, provide within seven days documents, data and information regarding the same.

The PSC is making every effort to obtain this information on an expedited basis. Following receipt of the requested documents and data, the PSC requests the

Hon. Freda L. Wolfson, U.S.D.J.

October 18, 2019

Page 2

opportunity to supplement its briefing and provide the relevant evidence to the Court for consideration when addressing the pending *Daubert* motions.

Thank you for your consideration of these matters. Should the Court have any questions, the PSC stands ready to respond in any way that might assist the Court.

Very truly yours,

/s/ P. Leigh O'Dell
P. Leigh O'Dell

/s/ Michelle A. Parfitt
Michelle A. Parfitt

cc: Susan Sharko, Esq. (via email without enclosure)
John Beisner, Esq. (via email without enclosure)
Tom Locke, Esq. (via email without enclosure)
The Plaintiffs' Steering Committee (via email without enclosure)

Exhibit A



OUR COMPANY

Johnson & Johnson Consumer Inc. to Voluntarily Recall A Single Lot of Johnson's Baby Powder in The United States

Company is Acting Out of an Abundance of Caution

Recall Limited to One Lot of Bottles Produced and Shipped in the U.S. in 2018

NEW BRUNSWICK, NJ, October 18, 2019 – Out of an abundance of caution, Johnson & Johnson Consumer Inc. (JJCI) announced that it is initiating a voluntary recall in the United States of a single lot of its Johnson's Baby Powder in response to a U.S. Food and Drug Administration (FDA) test indicating the presence of sub-trace levels of chrysotile asbestos contamination (no greater than 0.00002%) in samples from a single bottle purchased from an online retailer. Despite the low levels reported and in full cooperation and collaboration with the FDA, JJCI is initiating this voluntary recall of Lot #22318RB of Johnson's Baby Powder, from which the tested sample was taken.

In parallel, JJCI has immediately initiated a rigorous, thorough investigation into this matter, and is working with the FDA to determine the integrity of the tested sample, and the validity of the test results. At this early stage of the investigation, JJCI:

- Cannot confirm if cross-contamination of the sample caused a false positive.
- Cannot confirm whether the sample was taken from a bottle with an intact seal or whether the sample was prepared in a controlled environment.
- Cannot confirm whether the tested product is authentic or counterfeit.

JJCI has a rigorous testing standard in place to ensure its cosmetic talc is safe and years of testing, including the FDA's own testing on prior occasions--and as recently as last month--found no asbestos. Thousands of tests over the past 40 years repeatedly confirm that our consumer talc products do not contain asbestos. Our talc comes from ore sources confirmed to meet our stringent specifications that exceed industry standards. Not only do we and our suppliers routinely test to ensure our talc does not contain asbestos, our talc has also been tested and confirmed to be asbestos-free by a range of independent laboratories, universities and global health authorities.

For 133 years, the Johnson & Johnson Family of Companies have been committed to putting the needs and well-being of the people we serve first, and we will continue to do so.

If you or someone you provide care for owns a bottle of Johnson's Baby Powder Lot #22318RB, you are advised to discontinue use of the product. For refund information, contact the Johnson & Johnson Consumer Care Center at www.johnsonsbaby.com or by calling +1 (866) 565-2229.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the voluntary recall of one lot of Johnson's Baby Powder. The reader is cautioned not to rely on these forward-looking statements. The

forward-looking statements in this press release are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections Johnson & Johnson Consumer Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; manufacturing difficulties or delays, internally or within the supply chain; changes to applicable laws and regulations; changes in behavior and spending patterns of purchasers of health care products and services; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the company's most recently filed Quarterly Report on Form 10-Q and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Neither Johnson & Johnson Consumer Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. The Company expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Press Contacts:

Ernie Knewitz
(732) 524-1090

Jake Sargent
(202) 569-5086
JSargen3@ITS.JNJ.com

Investor Contacts:

Christopher DelOrefice
(732) 524-2955

Lisa Romanko
(732) 524-2034

All contents © Copyright Johnson & Johnson Services, Inc.1997-2019. All Rights Reserved.